目的探讨氟康唑、伊曲康唑、伏立康唑、酮康唑、特比萘芬、两性霉素B、咪康唑、5-氟胞嘧啶对36株足癣致病菌的体外抑菌特征。方法对55例临床疑似足癣患者行真菌镜检、培养和鉴定。分别应用美国临床实验室标准化委员会(Clinical and Labo...目的探讨氟康唑、伊曲康唑、伏立康唑、酮康唑、特比萘芬、两性霉素B、咪康唑、5-氟胞嘧啶对36株足癣致病菌的体外抑菌特征。方法对55例临床疑似足癣患者行真菌镜检、培养和鉴定。分别应用美国临床实验室标准化委员会(Clinical and Laboratory Standards Institute,CLSI)M38-A2和M27-A3方案针对其中的皮肤癣菌和念珠菌,检测8种药物对不同真菌的最低抑菌浓度(Minimum inhibitory concentration,MIC)。结果镜检及培养均为阳性的真菌36株,计8个菌种:红色毛癣菌、须癣毛癣菌、石膏样小孢子菌、絮状毛癣菌、羊毛状小孢子菌、白念珠菌、光滑念珠菌、克柔念珠菌;属2大类:皮肤癣菌、念珠菌。8种药物对8种真菌的MIC值比较,抑菌效果存在显著差异(P<0.05)。皮肤癣菌和念珠菌2大类比较,除伊曲康唑外(P>0.05),其余7种药物的抑菌效果存在显著差异(P<0.05)。其中,特比萘芬对皮肤癣菌的平均秩次最小。5-氟胞嘧啶对念珠菌的平均秩次最小。结论上述8种药物的体外药敏实验提示,8种药物对8种真菌的抑菌效果存在显著差异。除伊曲康唑外,其余7种药物对皮肤癣菌和念珠菌的抑菌效果存在显著差异。相对而言,特比萘芬对皮肤癣菌抑菌效果更好,5-氟胞嘧啶对念珠菌抑菌效果更好。展开更多
Brainstem gliomas comprise both slow-growing and highly aggressive tumors,the latter carrying a dismal prognosis of approximately 10 months in children.Given their common locations along the brainstem,they are often n...Brainstem gliomas comprise both slow-growing and highly aggressive tumors,the latter carrying a dismal prognosis of approximately 10 months in children.Given their common locations along the brainstem,they are often not amenable to surgical resection.There are currently a host of exploratory therapies under investigation ranging from immunotherapy,small molecular inhibitors,epigenetic-modifying agents,and radiation protocols to combat these difficult-to-treat tumors.Recent discoveries highlighting the role of H3 histone mutations in diffuse midline glioma oncogenesis have yielded a variety of new targetable antigens and aberrant signaling pathways.Although many of these studies have shown promise in terms of inhibiting tumor growth and disease progression,results to date have been modest in their ability to translate into meaningful clinical benefit.This review will serve as an updated report on the current state of literature concerning pre-clinical and clinical therapies being investigated for brainstem glioma.In addition,this review will serve as a guide for clinicians as we review the evolving nomenclature of brainstem gliomas,commonly presenting symptoms,diagnostic tools,and standard therapies.展开更多
文摘Brainstem gliomas comprise both slow-growing and highly aggressive tumors,the latter carrying a dismal prognosis of approximately 10 months in children.Given their common locations along the brainstem,they are often not amenable to surgical resection.There are currently a host of exploratory therapies under investigation ranging from immunotherapy,small molecular inhibitors,epigenetic-modifying agents,and radiation protocols to combat these difficult-to-treat tumors.Recent discoveries highlighting the role of H3 histone mutations in diffuse midline glioma oncogenesis have yielded a variety of new targetable antigens and aberrant signaling pathways.Although many of these studies have shown promise in terms of inhibiting tumor growth and disease progression,results to date have been modest in their ability to translate into meaningful clinical benefit.This review will serve as an updated report on the current state of literature concerning pre-clinical and clinical therapies being investigated for brainstem glioma.In addition,this review will serve as a guide for clinicians as we review the evolving nomenclature of brainstem gliomas,commonly presenting symptoms,diagnostic tools,and standard therapies.
